July 21, 2014
1 min read

HARBOR study: visual, anatomic improvements maintained at 2 years

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Ranibizumab improved vision for 2 years in patients with subfoveal neovascular age-related macular degeneration, according to results of the HARBOR study.

The randomized, controlled, multicenter phase 2 study included 1,098 patients 50 years and older with treatment-naïve subfoveal wet AMD.

Patients were randomly assigned to one of four groups:  0.5 mg monthly injections (group one), 0.5 mg as needed (group two), 2 mg monthly (group three) or 2 mg as needed (group four).

Outcome measures included mean change in best corrected visual acuity from baseline at 12 and 24 months, percentage of patients who gained 15 or more letters of BCVA, mean number of injections and mean change in central foveal thickness from baseline.

Mean number of injections through 24 months was 21.4 in group one, 13.3 in group two, 21.6 in group three and 11.2 in group four. The second group required a mean 5.6 injections and the fourth group required 4.3 injections at 24 months, according to the researchers.

At 24 months, mean gain in BCVA from baseline was 9.1 letters in group one, 7.9 letters in group two, eight lines in group three and 7.6 lines in group four.

The percentage of patients who gained at least 15 letters was 34.5% in the first group, 33.1% in the second group, 37.6% in the third group and 34.8% in the fourth group.

Snellen equivalent visual acuity was 20/40 or better in 44% to 52% of patients at 12 months and in 45% to 50% at 24 months, according to the researchers.

Disclosure: See the study for a full list of all authors’ relevant financial disclosures.